Equities analysts predict that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will post sales of $75.59 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sucampo Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $73.00 million and the highest estimate coming in at $77.70 million. Sucampo Pharmaceuticals posted sales of $73.02 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3.5%. The company is scheduled to report its next quarterly earnings results on Wednesday, March 14th.

According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year sales of $75.59 million for the current financial year, with estimates ranging from $250.00 million to $255.10 million. For the next financial year, analysts expect that the business will post sales of $261.10 million per share, with estimates ranging from $257.49 million to $263.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the previous year, the business earned $0.30 EPS. The company’s revenue was up 5.9% compared to the same quarter last year.

SCMP has been the topic of a number of research reports. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Tuesday, October 17th. Mizuho lifted their price target on shares of Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, December 8th. UBS lowered their price target on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Finally, initiated coverage on shares of Sucampo Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 price target on the stock. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Sucampo Pharmaceuticals presently has an average rating of “Buy” and an average price target of $16.60.

Sucampo Pharmaceuticals (SCMP) opened at $16.50 on Thursday. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.70. The firm has a market capitalization of $766.01, a P/E ratio of 11.13, a PEG ratio of 4.84 and a beta of 1.47. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.

In related news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.13% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaMark Advisors LLC raised its stake in shares of Sucampo Pharmaceuticals by 25.4% during the second quarter. AlphaMark Advisors LLC now owns 98,400 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 19,900 shares during the last quarter. Swiss National Bank raised its stake in shares of Sucampo Pharmaceuticals by 22.3% during the second quarter. Swiss National Bank now owns 43,859 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 8,000 shares during the last quarter. Texas Permanent School Fund raised its stake in shares of Sucampo Pharmaceuticals by 2.2% during the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 398 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Sucampo Pharmaceuticals by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after acquiring an additional 15,528 shares during the last quarter. Finally, Eqis Capital Management Inc. raised its stake in shares of Sucampo Pharmaceuticals by 28.5% during the third quarter. Eqis Capital Management Inc. now owns 40,651 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 9,012 shares during the last quarter. Institutional investors and hedge funds own 65.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Quarterly Sales of $75.59 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/14/sucampo-pharmaceuticals-inc-scmp-expected-to-post-quarterly-sales-of-75-59-million.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.